High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: Predictability and relation with disease advancement

Cancer Immunology, Immunotherapy

Volumn 50, Issue 3, 2001, Pages 134-140

  Pandolfino, Marie Christine ^a,b   Labarrière, Nathalie ^b   Tessier, Marie Hélène ^c   Cassidanius, Alain ^a   Bercegeay, Sylvain ^a   Lemarre, Philippe ^a   Dehaut, Frédéric ^a   Dréno, Brigitte ^a,b,c   Jotereau, Francine ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE   (France)

^c Departement de Dermatol du C   (France)

Author keywords

Cytokines; Immunotherapy; Lymphocytes

Indexed keywords

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CYTOKINE RELEASE; DISSEMINATED CANCER; HUMAN; HUMAN CELL; LYMPH NODE BIOPSY; LYMPHOCYTE COUNT; MELANOMA; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0035018605     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006683     Document Type: Article

References (26)

1. 1. Aruga A, Shu S, Chang AE (1995) Tumor-specific granulocyte/ macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 41: 317-324
2. 2. Chin Y, Janssens J, Smeyers E, Bleus J, Zhang J, Raus J (1992) Large scale expansion of human tumor infiltrating lymphocytes with surface-modified stimulator cells for adoptive immunotherapy Anticancer Res 12: 733-736
3. 3. Fonteneau JE, Le Drean E, Le Guiner S, Gervois N, Diez E, Jotereau F (1997) Heterogeneity of biologic responses of melanoma-specific CTL. J Immunol 159: 2831-2839
4. 4. Gervois N, Guilloux Y, Diez E, Jotereau F (1996) Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 183: 2403-2407
5. 5. Gervois N, Heuze F, Diez E, Jotereau F (1990) Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 20: 825-831
6. 6. Gervois N, Labarriere N, Le Guiner S, Pandolfino MC, Fonteneau JF, Guilloux Y, Diez E, Dreno B, Jotereau F (2000) High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clin Cancer Res 6: 1459-1467
7. 7. Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T (1996) Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 191: 131-142
8. 8. Itoh Y, Germain RN (1997) Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells. J Exp Med 186: 757-766
9. 9. Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY, LeMevel B (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10: 405-411
10. 10. Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159: 197-207
11. 11. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA (2000) Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 23: 17-27
12. 12. Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, Le Guiner S, Fonteneau JF, Dreno B, Jotereau F (1997) Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 158: 1238-1245
13. 13. Labarriere N, Pandolfino MC, Raingeard D, Le Guiner S, Diez E, Le Drean E, Dreno B, Jotereau F (1998) Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes. Int J Cancer 78: 209-215
14. 14. Lynch DH, Miller RE (1991) Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur J Immunol 21: 1403-1410
15. 15. Melief CJ, Kast WM (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145: 167-177
16. 16. Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ (1998) Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/ macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J Immunol 160: 334-344
17. 17. Pandolfino MC, Viret C, Gervois N, Guilloux Y, Davodeau F, Diez E, Jotereau F (1992) Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol 22: 1795-1802
18. 18. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190: 705-715
19. 19. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188: 1641-1650
20. 20. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680
21. 21. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159-1166
22. 22. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, Rosenberg SA, Topalian SL (1994) In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 12: 1475-1483
23. 23. Tessier MH, Pandolfino MC, Jotereau F, Boudart D, Litoux P, Dreno B (1996) Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma. Eur J Cancer 32A: 735-736
24. 24. Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127-141
25. 25. Topalian SL, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714-3725
26. 26. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162: 2227-2234